C-GHJXLyGenesis
cell therapy, lymph node bioreactors, organ regeneration
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GHJX
C-GHJXC-GHJXcell therapy, lymph node bioreactors, organ regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
LyGenesis cell therapy, lymph node bioreactors, organ regeneration
LyGenesis is a clinical-stage cell therapy company developing therapies that transform a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Its programs target unmet needs including Type 1 diabetes, end stage liver disease, renal disease, and thymus aging. The company states that its allogeneic cell therapies engraft, proliferate, and form functional ectopic organs that recapitulate native organ function.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
LyGenesis — Translational · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic